AFMD Affimed N.V.

$AFMD after doing more research, the only thing I could come to conclusion is that they have way more IPs than we actually thought that are actually worth some money. AFM 13 AFM 28, AFM 24 were pretty much the only thing we discussed. The rest of the platform still holds patents and preclinical assets, including the platform ice with those three assets alone, it’s worth quite a bit. Everything else is preclinical. It’s still worth $5 to $10 million. I truly think this company is going to survive through some kind of merger or restructuring.

$AFMD since they renewed, the calculation will change too. Now it's likely two scenarios:1. (Bull case) they will reemerge without any restructuring and will regain compliance with SEC or 2. They will do some restructuring or reverse merger to change the corporate structure. We may be wiped out (worst case aka currently priced in) or get out stronger as shareholders of new company.

$AFMD IP: PTCL This promising combination has applicability not only in HL, but also in other CD30 positive lymphomas such as peripheral T-cell lymphoma (PTCL), which can also be resistant to conventional therapies, has a high risk of relapse, and where few products are approved. Generating clinical proof-of-concept in PTCL would also highlight a potential path to increasing the commercial potential of the combination by two to three-fold in comparison to.. double-refractory HL.

$AFMD no body celebrating a 100% gain day which is also the first green day in.... a few months🤣🤣🤣?

$AFMD I can't remember Roche got license for AFM24. But according to Patsnap Synapase, it now holds license to AFM24. Also seems the parent Affimed N.V. holds license for all clinical assets.

$AFMD Upcoming: - 720 mg/week cohort (up to 34 patients, recruitment began Q1 2025) – data was expected in H1 2026. Since that window has now passed (it's late September 2026), this data may have been released or is imminent, but I [Brave AI] don't have confirmation of a specific release date in my search results. Optional triplet cohorts (adding ramucirumab or docetaxel) – if opened, readouts could come in late 2026 or early 2027. In short, the primary cohort results are already out. The key pending data is the 720 mg cohort readout, which was targeted for the first half of 2026.

$AFMD As of September 2026 ::: -The collaboration between Affimed and Roche to study AFM24 in combination with atezolizumab (Tecentriq) is still in effect and actively ongoing as of late 2023. Current Status: The Phase 1/2a clinical trial (AFM24-102) evaluating this combination in EGFR-expressing solid tumors remains active. Strategic Focus: In June 2023, Affimed announced it would focus clinical development on combination approaches, specifically adding an EGFR mutant NSCLC cohort to the ongoing AFM24-102 study to evaluate synergies with atezolizumab. Recent Updates: Positive data from the trial in heavily pre-treated EGFR-wildtype NSCLC patients was reported in December 2023, with enrollment continuing in the NSCLC cohort while enrollment was discontinued in gastric and pancreatic/biliary tract cohorts.

$AFMD as much I want to believe this is it !could be just people closing their positions let’s wait and see It’s all we can do I won’t be closing mine till either we get paid or we are no longer a ticker !!

$AFMD plus the have hundreds of patents !! Pharma is on a huge patent hunt ! Affimed doesn’t have “a few patents.” They have an entire patent ecosystem, covering: • ICE platform (Innate Cell Engagers) • NK cell pre‑complexing • NK activation + targeting mechanisms • EGFR innate engager architecture (AFM24) • CD30 innate engager architecture (AFM13) • AML innate engager architecture (AFM28) • solid tumor ICE architecture (AFM32) • manufacturing methods • vector engineering • bispecific tetravalent constructs • cord‑blood NK combination IP • Roivant ICE collaboration IP • Genentech NK engager collaboration IP • Artiva AlloNK + acimtamig combination IP • multiple unnamed preclinical ICE molecules • territory‑specific rights maps • clinical data packages protected under CDA This is hundreds of patents and applications — not a handful.